Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Rauvolfia serpentina, the Indian snakeroot, devil pepper, serpentine wood, Sarpagandha (as known locally) or Chandrika, is a species of flower in the milkweed family Apocynaceae. It is native to the Indian subcontinent and East Asia (from India to Indonesia). Rauvolfia is a perennial undershrub widely distributed in India in the sub-Himalayan regions up to 1,000 metres (3,300 ft). Sarpagandha is used in folk medicine in India for centuries to treat a wide variety of maladies, including snake and insect bites, febrile conditions, malaria, abdominal pain, and dysentery. It was also used as a uterine stimulant, febrifuge, and cure for insanity. The plant was mentioned in Hindu manuscripts as long ago as 1000 BCE.
tumefaciens without explanation to "B6", a strain now properly classified as Agrobacterium radiobacter (genomovar 4), causing misled researchers to propose the synonymization of the two. The original type strain of A. tumefaciens, reinstated in 2023, belongs to genomovar 1. Another strain of "A. tumefaciens" commonly used in early research was C58, which belongs to genomovar 8. For a review of the currently-known structure of the species complex, see Vargas Ribera et al. (2024), which also lists names that have been separately proposed for the genomovars. This article cites a great number of sources that do not distinguish among the genomovars. Most text in this article should be treated as describing the species complex as a whole.
He also initiated the President's Emergency Plan for AIDS Relief, in 2003, to address the global AIDS epidemic. The September 11 attacks during 2001 decisively reshaped his administration, resulting in the start of the war on terror and the creation of the Department of Homeland Security. Bush ordered the invasion of Afghanistan in an effort to overthrow the Taliban, destroy al-Qaeda, and capture Osama bin Laden. He signed the Patriot Act, expanding surveillance powers for suspected terrorists. He also ordered the 2003 invasion of Iraq to overthrow Saddam Hussein's regime, citing claims that it possessed weapons of mass destruction and had ties with al-Qaeda. Bush later signed the Medicare Modernization Act, which created Medicare Part D. In 2004, Bush was re-elected president in a close race, beating Democratic opponent John Kerry and winning the popular vote. During his second term, Bush negotiated various free trade agreements, appointed John Roberts and Samuel Alito to the Supreme Court, and sought major changes to Social Security and immigration laws, both of which ultimately failed in Congress. He was widely criticized for his administration's handling of Hurricane Katrina and revelations of torture against detainees at Abu Ghraib prison in Iraq. Amid his unpopularity, the Democrats regained control of Congress in the 2006 elections. In January 2007, Bush launched a surge of troops in Iraq.
==== Cruel and unusual ==== On occasion, difficulties inserting the intravenous needles have also occurred, with personnel sometimes taking over half an hour to find a suitable vein. Typically, the difficulty is found in convicts with type 2 diabetes or a history of intravenous drug use. Opponents argue that excessive time taken to insert intravenous lines is tantamount to cruel and unusual punishment. In addition, opponents point to instances where the intravenous line has failed or when adverse reactions to drugs or unnecessary delays have happened during the process of execution. On December 13, 2006, Angel Nieves Diaz was not executed successfully in Florida using a standard lethal-injection dose. Diaz was 55 years old and had been sentenced to death for murder. Diaz did not succumb to the lethal dose even after 35 minutes, necessitating a second dose of drugs to complete the execution. At first, a prison spokesman denied Diaz had suffered pain and claimed the second dose was needed because Diaz had some sort of liver disease. After performing an autopsy, the medical examiner, William Hamilton, stated that Diaz's liver appeared normal, but that the needle had pierced through Diaz's vein into his flesh. The deadly chemicals had subsequently been injected into soft tissue rather than into the vein.
== Variations and related drinks == Calvados and applejack are strong liquors distilled from cider. They differ in their geographical origin and their method of distillation. Calvados is made throughout Normandy, not just in the Calvados département. It is made from cider by double distillation. In the first pass, the result is a liquid containing 28–30% alcohol. After the second pass, the concentration of alcohol is about 40%. Applejack is a strong alcoholic beverage made in North America by concentrating cider, either by the traditional method of freeze distillation or by true evaporative distillation. In traditional freeze distillation, a barrel of cider is left outside during the winter. When the temperature is low enough, the water in the cider starts to freeze. If the ice is removed, the (now more concentrated) alcoholic solution is left behind in the barrel. If the process is repeated often enough, and the temperature is low enough, the alcohol concentration is raised to 20–30% alcohol by volume. Home production of applejack is popular in Europe. Ice cider (French: cidre de glace), originating in Quebec and inspired by ice wine, has become a Canadian speciality, now also being produced in England. For this product, the apples are frozen either before or after being harvested. Its alcohol concentration is 9–13% ABV. Cidre de glace is considered a local speciality in Quebec and can fetch high prices on the international market. In Canada, ice cider is produced by natural, outdoor freezing.
Sources: en.wikipedia.org
First-generation NSAAs including bicalutamide, flutamide, and nilutamide are all synthetic, nonsteroidal anilide derivatives and structural analogues of each other. Bicalutamide is a diarylpropionamide while flutamide is a monoarylpropionamide and nilutamide is a hydantoin. Bicalutamide and flutamide, though not nilutamide, can also be classified as toluidides. All three of the compounds share a common 3-trifluoromethylaniline moiety. Bicalutamide is a modification of flutamide in which a 4-fluorophenylsulfonyl moiety has been added and the nitro group on the original phenyl ring has been replaced with a cyano group. Topilutamide, also known as fluridil, is another NSAA that is closely related structurally to the first-generation NSAAs, but, in contrast to them, is not used in the treatment of prostate cancer and is instead used exclusively as a topical antiandrogen in the treatment of pattern hair loss.
Complementary protein combinations make for delicious recipes – they are combinations that formed the basis of the world's traditional cuisines. We use them naturally in our cooking without even being aware of it. The three most common complementary protein combinations are: Grains (rice, corn, wheat, barley, etc.) + legumes (peas, beans, lentils) Grains and milk products Seeds (Sesame or sunflower) +legumes In 1975, both Vogue and American Journal of Nursing carried articles describing the principles and practice of protein combining. For a time, The American National Research Council and the American Dietetic Association (ADA) cautioned vegetarians to be sure to combine their proteins. Protein combining reached the pages of a general chemistry textbook in 1982:
In February 1983 he fell over in the melée (he said at the time that he was pushed) when CND protestors surrounded a meeting of Newbury Conservatives, a propaganda gift, and on Good Friday 1983 he was filmed in West Berlin looking over the wall to the communist east, distracting attention from CND's linking of arms round Greenham Common that day. With a general election looming, Heseltine was keen to associate Labour with CND, and CND with communists and the Soviet Union (ignoring earlier comments by Party Chairman Cecil Parkinson that this was "manifest nonsense" – the media did not pick up on this). He made such a claim in a speech at Exeter in April 1983, and distributed to Tory candidates information about the background of leading members of CND. This had been assembled by Ray Whitney MP, but some of it was suspected of having come from intelligence sources. MI5 agent Cathy Massiter later wrote, in 1985 in The Observer, that from 1981 onwards and especially from 1983 she had been asked to pass on to DS19 (the propaganda unit at the Ministry of Defence) information obtained by wiretaps and by an MI5 mole in CID. MI5 bosses refused to pass on classified material about security matters but agreed to pass on information about the political links of CND members. Even this was in breach of the 1952 Directive from Home Secretary David Maxwell-Fyfe that the security services not provide information for party political purposes.
Seizures Delay in development Cardiac issues Swallowing difficulty Neurological problems Fukuyama congenital muscular dystrophy also affects the nervous system and various associated parts. FCMD affects normal development of the brain producing a broadly smooth, bumpy shaped cortex named cobblestone lissencephaly as well as various other malformations, notably micropolygyria. Children also experience delayed myelination in the brain.
There are two diametrically opposed definitions of the dog year, primarily used to approximate the equivalent age of dogs and other animals with similar life spans. Both are based upon a popular myth regarding the aging of dogs that states that a dog ages seven years in the time it takes a human to age one year.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.